Format

Send to

Choose Destination
Eur J Cancer. 2019 Jan;106:144-159. doi: 10.1016/j.ejca.2018.11.002. Epub 2018 Dec 5.

Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer.

Author information

1
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Radiological, Pathological and Oncological Science, Sapienza University of Rome, Italy. Electronic address: arsela20@hotmail.it.
2
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: rebecca.tay@christie.nhs.uk.
3
Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France. Electronic address: roberto.ferrara@gustaveroussy.fr.
4
Laboratory of Immunomonitoring in Oncology, UMS 3655 CNRS/US 23 INSERM, Gustave Roussy, Villejuif, France; Faculty of Pharmacy, University Paris-Saclay, Chatenay-Malabry, France. Electronic address: nathalie.chaput@gustaveroussy.fr.
5
Cancer Medicine Department, Gustave Roussy, Villejuif, France; Paris-Sud University, Orsay, France. Electronic address: benjamin.besse@gustaveroussy.fr.
6
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Department of Medical Oncology, Manchester University NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK. Electronic address: raffaele.califano@christie.nhs.uk.

Abstract

Immune checkpoint blockade has been a pivotal development in the management of advanced non-small-cell lung cancer (NSCLC). Although durable antitumour activity and improved survival have been observed in a subset of patients, there is a need for additional predictive biomarkers to improve patient selection and avoid toxicity in potential non-responders. This review will address the use and limitations of tumour programmed death-ligand 1 expression as a predictive biomarker and review emerging biomarker strategies specifically related to NSCLC including genetic alterations (tumour mutation burden, loss and gain activated mutations), tumour-related factors (tumour microenvironment) and factors related to the host immune system. Novel approaches in biomarker detection such as peripheral blood monitoring will also be reviewed.

KEYWORDS:

Immunotherapy; Lung cancer; Microsatellite instability; NSCLC; PD-L1; Predictive biomarkers; Tumour microenvironment; Tumour mutational burden

PMID:
30528799
DOI:
10.1016/j.ejca.2018.11.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center